All updates
All updates
today 37文献与产业新闻评分3232 Sanofi strikes Cheplapharm deal to divest 20 older medicines as CEO pushes for innovation
文献与产业新闻评分1010 AbbVie chips in for neurology advocacy through PGA Tour birdie campaign
文献与产业新闻评分3030 Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure
文献与产业新闻评分2626 Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
文献与产业新闻评分2828 Newly formed Jaguar acquires Afib device assets from J&J
文献与产业新闻评分1111 Olympic skier Lindsey Vonn joins up with Vertex for pain campaign
文献与产业新闻评分4040 Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
文献与产业新闻评分4646 GSK doubles down on Chimagen with $750M multiple myeloma wager
中文产业新闻精选Chinese source评分4040 200亿！强生骨科王牌DePuy Synthes，或将易主Apollo
文献与产业新闻精选评分5252 Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
文献与产业新闻评分1919 Abbott agrees to settlement over closure of largest baby formula plant in the U.S.
文献与产业新闻评分1313 Lilly cans early experimental obesity drug after ‘high bar’ not met
文献与产业新闻评分1616 Shionogi taps The Bloc for omnichannel campaign backing COVID-19 pill Xocova
文献与产业新闻评分2424 GSK makes ‘difficult decision’ to shutter German flu vaccine manufacturing site
文献与产业新闻精选评分3535 Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
文献与产业新闻评分99 No more Nordisk as Novo goes it alone amid rebranding push
文献与产业新闻精选评分3535 Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
文献与产业新闻评分1616 Takeda’s Plump, GV’s Yeshwant announce retirement plans
文献与产业新闻精选评分5454 With deep pockets, Solstice takes next-gen CTLA-4 into neoadjuvant treatment
文献与产业新闻评分3131 Encoded preps for Dravet launch with $275M round: Finance Report
文献与产业新闻评分1414 STAT+: Up and down the ladder: The latest comings and goings
文献与产业新闻评分3030 Owkin, Servier ink oncology R&D deal to guide discovery and trial design
文献与产业新闻评分1717 STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
文献与产业新闻评分1818 STAT+: Cancer drug shortages keep disrupting patient care
文献与产业新闻评分1818 Fierce Pharma Asia—Takeda’s R&D leadership change; Daiichi’s $1.3B court win; New Samsung Bio contract
文献与产业新闻评分2020 CDMO Argonaut sheds life sciences, diagnostics division for undisclosed sum
文献与产业新闻评分1313 Singapore launches biotech-focused Boston hub to build on 'centuries-old bond'
文献与产业新闻评分2121 Biotech’s 2026 IPOs deliver broad gains through August
文献与产业新闻评分1515 Chutes & Ladders—Longtime Takeda R&D chief to depart next June
文献与产业新闻评分2121 STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
文献与产业新闻评分2828 Swiss CDMOS making moves: Lonza bets on new US facility, CordenPharma scales injectables with €80M
文献与产业新闻评分1616 Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
文献与产业新闻评分1717 Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
文献与产业新闻评分2828 Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
文献与产业新闻评分1616 Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes